These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7461018)

  • 21. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
    Branch RA; Shand DG; Wilkinson GR; Nies AS
    J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments.
    Watanabe T; Maeda K; Kondo T; Nakayama H; Horita S; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2009 Jul; 37(7):1471-9. PubMed ID: 19364828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lean body mass as a predictor of drug dosage. Implications for drug therapy.
    Morgan DJ; Bray KM
    Clin Pharmacokinet; 1994 Apr; 26(4):292-307. PubMed ID: 8013162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data.
    Somogyi A; Eichelbaum M; Gugler R
    Eur J Clin Pharmacol; 1982; 22(1):85-90. PubMed ID: 7094978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Definition of pharmacokinetic parameters: influence of the sampling site.
    Weiss M
    J Pharmacokinet Biopharm; 1984 Apr; 12(2):167-75. PubMed ID: 6491899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of route of administration and blood flow on hepatic drug elimination.
    Shand DG; Kornhauser DM; Wilkinson GR
    J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Principles and clinical application of assessing alterations in renal elimination pathways.
    Tett SE; Kirkpatrick CM; Gross AS; McLachlan AJ
    Clin Pharmacokinet; 2003; 42(14):1193-211. PubMed ID: 14606929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance.
    Hallifax D; Houston JB
    Drug Metab Dispos; 2006 Nov; 34(11):1829-36. PubMed ID: 16882765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating reduced availability due to first pass elimination from relative total clearance and renal clearance.
    Brockmeier D
    Eur J Clin Pharmacol; 1988; 35(4):397-400. PubMed ID: 3197748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of hepatic clearance with the account of drug-protein binding kinetics.
    Berezhkovskiy LM
    J Pharm Sci; 2012 Oct; 101(10):3936-45. PubMed ID: 22767378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-dependent propranolol clearance in perfused rat liver.
    Iwamoto K; Watanabe J; Satoh M; Deguchi N; Sugiyama H
    Biochem Pharmacol; 1986 Apr; 35(7):1149-52. PubMed ID: 3964295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.
    Pang KS; Rowland M
    J Pharmacokinet Biopharm; 1977 Dec; 5(6):625-53. PubMed ID: 599411
    [No Abstract]   [Full Text] [Related]  

  • 34. Application of Organ Clearance to Estimation of the In Vivo Hepatic Extraction Ratio.
    Mehvar R
    Curr Clin Pharmacol; 2016; 11(1):47-52. PubMed ID: 26278971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of creatinine clearance when urine cannot be collected.
    Jelliffe RW
    Lancet; 1971 May; 1(7706):975-6. PubMed ID: 4102307
    [No Abstract]   [Full Text] [Related]  

  • 36. Reduced hepatic clearance of propranolol induced by chronic carbon tetrachloride treatment in rats.
    Iwamoto K; Watanabe J; Araki K; Satoh M; Deguchi N
    J Pharmacol Exp Ther; 1985 Aug; 234(2):470-5. PubMed ID: 4020680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
    Rasool MF; Khalil F; Läer S
    Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive assessment in vivo of hepatic drug metabolism in health and disease.
    Vesell ES
    Ann N Y Acad Sci; 1984; 428():293-307. PubMed ID: 6378027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discussions on the hepatic well-stirred model: Re-derivation from the dispersion model and re-analysis of the lidocaine data.
    Dong J; Park MS
    Eur J Pharm Sci; 2018 Nov; 124():46-60. PubMed ID: 30102979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.
    Huh Y; Smith DE; Feng MR
    Xenobiotica; 2011 Nov; 41(11):972-87. PubMed ID: 21892879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.